And in cancer-associated fibroblast (CAF)-rich tumors, such as breast cancer, lung cancer and colorectal cancer, setanaxib more effectively counteracts CAF-mediated immunosuppression than TGFβ1 inhibition, which is a key regulator of the CAF phenotype [376]. Here, TGFB1 is linked to cancer.